| 1. |
- Acevedo, Juan Pablo, et al.
(author)
-
Microtechnology applied to stem cells research and development
- 2018
-
In: Regenerative Medicine. - : FUTURE MEDICINE LTD. - 1746-0751 .- 1746-076X. ; 13:2, s. 233-248
-
Research review (peer-reviewed)abstract
- Microfabrication and microfluidics contribute to the research of cellular functions of cells and their interaction with their environment. Previously, it has been shown that microfluidics can contribute to the isolation, selection, characterization and migration of cells. This review aims to provide stem cell researchers with a toolkit of microtechnology (mT) instruments for elucidating complex stem cells functions which are challenging to decipher with traditional assays and animal models. These microdevices are able to investigate about the differentiation and niche interaction, stem cells transcriptomics, therapeutic functions and the capture of their secreted microvesicles. In conclusion, microtechnology will allow a more realistic assessment of stem cells properties, driving and accelerating the translation of regenerative medicine approaches to the clinic.
|
|
| 2. |
- Aldonyte, R, et al.
(author)
-
Effects of major human antiprotease alpha-1-antitrypsin on the motility and proliferation of stromal cells from human exfoliated deciduous teeth
- 2010
-
In: e-biomed. - : Future Medicine Ltd. - 1524-8909. ; 5:4, s. 633-643
-
Journal article (peer-reviewed)abstract
- AIM: Intrinsic tissue regeneration mechanisms are still not fully understood. The destruction/reconstruction processes are usually in fine balance; however, this can be easily destroyed, for example in the environment of chronic inflammation. One of the major proteins present at the inflammatory sites is the multifunctional protein alpha-1-antitrypsin (AAT). In this study, potential therapeutic effects of this major human antiprotease on progenitor cells are assessed. MATERIALS & METHODS: Stromal cells from human exfoliated deciduous teeth (SHEDs) were used, which are similar to the mesenchymal stromal cells isolated from other tissues. SHEDs were cultivated in the presence of subphysiological, physiological and inflammatory concentrations of AAT, and their proliferation and motility traits were assayed. Some intracellular signaling pathways, AAT internalization by SHEDs and their matrix metalloprotease profile were studied in parallel. RESULTS: Physiologic and inflammatory concentrations of AAT significantly increased the cell proliferation rate, induced phosphorylation of several key protein kinases and increased the amount of secreted active gelatinases. Moreover, cells exposed to physiologic and inflammatory levels of AAT were able to invade and migrate more efficiently. Subphysiologic AAT levels did not change cell behavior significantly. CONCLUSION: AAT at physiologic and inflammatory concentrations positively modulates the proliferation and motility of SHEDs in vitro. These results suggest the importance of AAT in the maintenance and regulation of tissue progenitor cells in vivo.
|
|
| 3. |
- Alexis, MD, et al.
(author)
-
The international translational regenerative medicine center
- 2012
-
In: Regenerative medicine. - : Future Medicine Ltd. - 1746-076X .- 1746-0751. ; 7:66 Suppl, s. 74-75
-
Journal article (peer-reviewed)abstract
- The International Translational Regenerative Medicine Center, an organizing sponsor of the World Stem Cell Summit 2012, is a global initiative established in 2011 by founding partners Karolinska Institutet (Stockholm, Sweden) and Beckman Research Institute at City of Hope (CA, USA) with a mission to facilitate the acceleration of translational research and medicine on a global scale. Karolinska Institutet, home of the Nobel Prize in Medicine or Physiology, is one of the most prestigious medical research institutions in the world. The Beckman Research Institute/City of Hope is ranked among the leading NIH-designated comprehensive cancer research and treatment institutions in the USA, has the largest academic GMP facility and advanced drug discovery capability, and is a pioneer in diabetes research and treatment.
|
|
| 4. |
- Bisson, Isabelle, et al.
(author)
-
Landscape of current and emerging cell therapy clinical trials in the UK: current status, comparison to global trends and future perspectives
- 2015
-
In: Regenerative Medicine. - : Future Medicine. - 1746-0751 .- 1746-076X. ; 10:2, s. 169-179
-
Journal article (peer-reviewed)abstract
- Cell Therapy Clinical Trial and Preclinical Research databases have been established by the Cell Therapy Catapult to document current and future cell therapy clinical trials in the UK. We identified 41 ongoing trials in April 2014, an increase of seven trials from April 2013. In addition, we identified 45 late-stage preclinical research projects. The majority of the clinical trials are early phase, primarily led by academic groups. The leading therapeutic areas are cancer, cardiology and neurology. The trends in the UK are also seen globally. As the field matures, more later phase and commercial studies will emerge and the challenges will likely evolve into how to manufacture sufficient cell quantities, manage complex logistics for multi-center trials and control cost.
|
|
| 5. |
- East, Emma, et al.
(author)
-
A 3D in vitro model reveals differences in the astrocyte response elicited by potential stem cell therapies for CNS injury
- 2013
-
In: Regenerative Medicine. - : Future Medicine Ltd.. - 1746-0751 .- 1746-076X. ; 8:6, s. 739-746
-
Journal article (peer-reviewed)abstract
- AIM: This study aimed to develop a 3D culture model to test the extent to which transplanted stem cells modulate astrocyte reactivity, where exacerbated glial cell activation could be detrimental to CNS repair success.MATERIALS & METHODS: The reactivity of rat astrocytes to bone marrow mesenchymal stem cells, neural crest stem cells (NCSCs) and differentiated adipose-derived stem cells was assessed after 5 days. Schwann cells were used as a positive control.RESULTS: NCSCs and differentiated Schwann cell-like adipose-derived stem cells did not increase astrocyte reactivity. Highly reactive responses to bone marrow mesenchymal stem cells and Schwann cells were equivalent.CONCLUSION: This approach can screen therapeutic cells prior to in vivo testing, allowing cells likely to trigger a substantial astrocyte response to be identified at an early stage. NCSCs and differentiated Schwann cell-like adipose-derived stem cells may be useful in treating CNS damage without increasing astrogliosis.
|
|
| 6. |
- Grapensparr, Liza, et al.
(author)
-
The therapeutic role of endothelial progenitor cells in Type 1 diabetes mellitus
- 2011
-
In: Regenerative Medicine. - 1746-0751 .- 1746-076X. ; 6:5, s. 599-605
-
Research review (peer-reviewed)abstract
- Pancreatic beta-cells sense and adjust the blood glucose level by secretion of insulin. In Type 1 diabetes mellitus, these insulin-producing cells are destroyed, leaving the patients incapable of regulating blood glucose homeostasis. At the time of diagnosis, most patients still have 20-30% of their original beta-cell mass remaining. These residual beta-cells are targets for intervention therapies aimed at preventing further autoimmune destruction, in addition to increasing the number of existing beta-cells. Such a therapeutic option is highly desirable since it may lead to a full recovery of newly diagnosed patients, with no need for further treatment with immunosuppressant drugs or exogenous insulin administration. In this article, we propose that endothelial progenitor cells, a cell type known to promote and support neovascularization following endothelial injury, may be used as part of a combinational stem cell therapy aimed to improve the vascularization, survival and proliferation of beta-cells.
|
|
| 7. |
- Hovatta, O
(author)
-
Global update: Sweden
- 2012
-
In: Regenerative medicine. - : Future Medicine Ltd. - 1746-076X .- 1746-0751. ; 7:6 Suppl, s. 140-2
-
Journal article (peer-reviewed)abstract
- Swedish researchers have been very active in the stem cell field for many years. They have pioneered areas such as clinical treatment of Parkinson’s disease, developmental biology including early stem cells, human embryonic stem cells, induced pluripotent stem cells and human mesenchymal stem cells. The Swedish Research Council and other funding organizations have been very positive for stem cell research, and there is a favorable law in Sweden regulating human embryonic stem cell research. Many groups have been active partners in projects funded by the European Commission. Clinical trials are ongoing with mesenchymal stem cells in graft versus host disease and osteogenesis imperfecta. Successful transplantations of trachea using a tissue-engineered product with cells cultured into a scaffold have been made recently [1] . Optimizing the stem cell type for these constructs is ongoing.
|
|
| 8. |
- Hug, Kristina, et al.
(author)
-
The ethics of withdrawal : The case of follow-up from first-in-human clinical trials
- 2017
-
In: Regenerative Medicine. - : Future Medicine Ltd. - 1746-0751 .- 1746-076X. ; 12:1, s. 25-36
-
Journal article (peer-reviewed)abstract
- This paper aims to analyze whether patients should be allowed to veto research-related use of medical data collected during routine follow-ups after their withdrawal from first-in-human clinical trials. Forms of withdrawal are identified and it is argued that the right to withdraw might be limited to some of these. The paper concludes that if veto right is denied, then: the research participant should be informed about the potential use of his/her follow-up data in case of his/her withdrawal and consent to it; follow-up should not be initiated for research purposes; compulsory use of follow-up data should imply the use of data anyway collected, requiring no additional effort from the patient; and before deciding about the veto right, investigation of concerned patients’ value preferences is needed.
|
|
| 9. |
- Hug, Kristina
(author)
-
Understanding voluntariness of consent in first-in-human cell therapy trials
- 2020
-
In: Regenerative Medicine. - : Future Medicine Ltd. - 1746-0751 .- 1746-076X. ; 15:5, s. 1647-1660
-
Journal article (peer-reviewed)abstract
- Consensus about contents of voluntariness in informed consent is lacking. Core criteria for voluntary consent are needed to ensure voluntariness. This article outlines the multidimensionality of voluntariness and identifies what could reduce voluntariness, especially in first-in-human clinical trials involving cell therapies. In such trials, truly voluntary consent is especially important because: such trials may involve risk of serious harm, while in case of some diseases, eligible patients often have potentially effective therapeutic alternatives; patients considering participation in high-risk first-in-human trials may feel more desperate and some may be dependent on their caregivers, including those in the family; implanted cells cannot be taken out of the patient's body if the patient wants to withdraw.
|
|
| 10. |
- Isasi, R., et al.
(author)
-
Disclosure and management of research findings in stem cell research and banking: policy statement
- 2012
-
In: Regenerative Medicine. - : Future Medicine Ltd. - 1746-0751 .- 1746-076X. ; 7:3, s. 439-448
-
Journal article (peer-reviewed)abstract
- Prompted by an increased interest of both research participants and the patient advocacy community in obtaining information about research outcomes and on the use of their biological samples; the international community has begun to debate the emergence of an ethical 'duty' to return research results to participants. Furthermore, the use of new technologies (e.g., whole-genome and -exome sequencing) has revealed both genetic data and incidental findings with possible clinical significance. These technologies together with the proliferation of biorepositories, provide a compelling rationale for governments and scientific institutions to adopt prospective policies. Given the scarcity of policies in the context of stem cell research, a discussion on the scientific, ethical and legal implications of disclosing research results for research participants is needed. We present the International Stem Forum Ethics Working Party's Policy Statement and trust that it will stimulate debate and meet the concerns of researchers and research participants alike.
|
|
